Filana Therapeutics, Inc.
FLNA
$1.91
-$0.09-4.50%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -61.82% | -36.22% | -22.74% | 13.76% | 7.39% |
| Gross Profit | 61.82% | 36.22% | 22.74% | -13.76% | -7.39% |
| SG&A Expenses | -62.67% | -55.99% | -40.39% | 342.45% | 397.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -62.28% | -46.71% | -31.14% | 46.66% | 42.97% |
| Operating Income | 62.28% | 46.71% | 31.14% | -46.66% | -42.97% |
| Income Before Tax | -273.73% | -500.27% | -701.24% | -51.95% | 74.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -273.73% | -500.27% | -701.24% | -51.95% | 74.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -273.73% | -500.27% | -701.24% | -51.95% | 74.96% |
| EBIT | 62.28% | 46.71% | 31.14% | -46.66% | -42.97% |
| EBITDA | 62.62% | 46.84% | 31.15% | -47.73% | -43.98% |
| EPS Basic | -327.53% | -505.98% | -553.86% | -30.52% | 81.00% |
| Normalized Basic EPS | -65.54% | -157.13% | -220.20% | -30.40% | 71.56% |
| EPS Diluted | -30.14% | -59.80% | -82.09% | 30.29% | 37.55% |
| Normalized Diluted EPS | -62.39% | -151.57% | -213.33% | -29.05% | 71.01% |
| Average Basic Shares Outstanding | 4.27% | 7.59% | 11.10% | 12.76% | 10.47% |
| Average Diluted Shares Outstanding | 3.65% | 6.93% | 10.40% | 12.03% | 11.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |